Adam Samuel Brown

Adam Samuel Brown

Auto-generated profile, based on publicly available information

Adam Samuel Brown

Department of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2017 in Scientific Data
Verified
Journal Article
Open access
PDF file
ABAdam S. Brown
Adam S. Brown
CPChirag J. Patel
Chirag J. Patel
Drug repositioning, the process of discovering, validating, and marketing previously approved drugs for new indications, is of growing interest to academia and industry due to reduced time and costs associated with repositioned drugs. Computational methods for repositioning are appealing because they putatively nominate the most promising candidate drugs for a given indication. Comparing the wide array of computational repositioning methods, however, is a challenge due to inconsistencies in method validation in the field. Furthermore, a common simplifying assumption, that all novel predictions are false, is intellectually unsatisfying and hinders reproducibility. We address this assumption by providing a gold standard database, repoDB, that consists of both true positives (approved drugs), and true negatives (failed drugs). We have made the full database and all code used to prepare it publicly available, and have developed a web application that allows users to browse subsets of the data (http://apps.chiragjpgroup.org/repoDB/).

1 May 2016 in Cell Reports
Verified
Journal Article
Open access
KSKaryn Schmidt
Karyn Schmidt
CJCailin E. Joyce
Cailin E. Joyce
FBFrank Buquicchio
Frank Buquicchio
ABAdam Brown
Adam Brown
JRJustin Ritz
Justin Ritz
CNCarl D. Novina
Carl D. Novina
Long non-coding RNAs (lncRNAs) have been implicated in numerous physiological processes and diseases, most notably cancers. However, little is known about the mechanism of many functional lncRNAs. We identified an abundantly expressed lncRNA associated with decreased melanoma patient survival. Increased expression of this lncRNA, SLNCR1, mediates melanoma invasion through a highly conserved sequence similar to that of the lncRNA SRA1. Using a sensitive technique we term RATA (RNA-associated transcription factor array), we show that the brain-specific homeobox protein 3a (Brn3a) and the androgen receptor (AR) bind within and adjacent to SLNCR1's conserved region, respectively. SLNCR1, AR, and Brn3a are specifically required for transcriptional activation of matrix metalloproteinase 9 (MMP9) and increased melanoma invasion. Our observations directly link AR to melanoma invasion, possibly explaining why males experience more melanoma metastases and have an overall lower survival in comparison to females.

9 January 2014 in Coral Reefs
Verified
Journal Article
Closed access
PDF file
CMCatherine McFadden
Catherine McFadden
ABA. S. Brown
A. S. Brown
CBC. Brayton
C. Brayton
CHC. B. Hunt
C. B. Hunt
LOL. P. van Ofwegen
L. P. van Ofwegen

22 November 2016 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
ABAdam S Brown
Adam S Brown
CPChirag J Patel
Chirag J Patel
Repositioning of previously approved drugs is a promising methodology because it reduces the cost and duration of the drug development pipeline and reduces the likelihood of unforeseen adverse events. Computational repositioning is especially appealing because of the ability to rapidly screen candidates in silico and to reduce the number of possible repositioning candidates. What is unclear, however, is how useful such methods are in producing clinically efficacious repositioning hypotheses. Furthermore, there is no agreement in the field over the proper way to perform validation of in silico predictions, and in fact no systematic review of repositioning validation methodologies. To address this unmet need, we review the computational repositioning literature and capture studies in which authors claimed to have validated their work. Our analysis reveals widespread variation in the types of strategies, predictions made and databases used as ‘gold standards’. We highlight a key weakness of the most commonly used strategy and propose a path forward for the consistent analytic validation of repositioning techniques.

27 September 2016 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
ABAdam S Brown
Adam S Brown
CPChirag J Patel
Chirag J Patel
Objective: Drug repositioning is a promising methodology for reducing the cost and duration of the drug discovery pipeline. We sought to develop a computational repositioning method leveraging annotations in the literature, such as Medical Subject Heading (MeSH) terms. Methods: We developed software to determine significantly co-occurring drug-MeSH term pairs and a method to estimate pair-wise literature-derived distances between drugs. Results We found that literature-based drug-drug similarities predicted the number of shared indications across drug-drug pairs. Clustering drugs based on their similarity revealed both known and novel drug indications. We demonstrate the utility of our approach by generating repositioning hypotheses for the commonly used diabetes drug metformin. Conclusion: Our study demonstrates that literature-derived similarity is useful for identifying potential repositioning opportunities. We provided open-source code and deployed a free-to-use, interactive application to explore our database of similarity-based drug clusters (available at http://apps.chiragjpgroup.org/MeSHDD/).

9 February 2016 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
ABAdam S. Brown
Adam S. Brown
SKSek Won Kong
Sek Won Kong
IKIsaac S. Kohane
Isaac S. Kohane
CPChirag J. Patel
Chirag J. Patel
Background: Repositioning approved drug and small molecules in novel therapeutic areas is of key interest to the pharmaceutical industry. A number of promising computational techniques have been developed to aid in repositioning, however, the majority of available methodologies require highly specific data inputs that preclude the use of many datasets and databases. There is a clear unmet need for a generalized methodology that enables the integration of multiple types of both gene expression data and database schema.Results: ksRepo eliminates the need for a single microarray platform as input and allows for the use of a variety of drug and chemical exposure databases. We tested ksRepo’s performance on a set of five prostate cancer datasets using the Comparative Toxicogenomics Database (CTD) as our database of gene-compound interactions. ksRepo successfully predicted significance for five frontline prostate cancer therapies, representing a significant enrichment from over 7000 CTD compounds, and achieved specificity similar to other repositioning methods.Conclusions: We present ksRepo, which enables investigators to use any data inputs for computational drug repositioning. ksRepo is implemented in a series of four functions in the R statistical environment under a BSD3 license. Source code is freely available athttp://github.com/adam-sam-brown/ksRepo. A vignette is provided to aid users in performing ksRepo analysis.